NASDAQ$CAI
Caris Life Sciences Inc · Q3 2025 earnings
Q3 2025 earnings ·
Briefing
Caris Life Sciences reported Q3 2025, revenue of $519.1M, net income of $24.3M, diluted EPS of 0.08.
For Q3 2025, Caris Life Sciences reported revenue of $519.1M, net income of $24.3M, diluted EPS was 0.08. Management discusses segment performance, capital allocation, and sector risks in the quarterly filing.
- Revenue $519.1M.
- Net income $24.3M.
- Diluted EPS 0.08.
Headline financials
Revenue & EPS history
Caris Life Sciences Inc · Revenue · Quarterly
$217M
Forward guidance
The quarterly filing discusses operating priorities, capital returns, and sector risks.
Tailwinds
- MD&A highlights liquidity and core business trends.
- Management commentary on segment performance.
Headwinds
- Macro, rates, or input costs may pressure margins.
- One-time items can affect YoY comparability.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 3 quarterly earnings reports · overlaid with Q3 2025
-5.8%
Avg return
Earnings day
-8.5%
Avg return
5 days after
-3.7%
Avg return
30 days after
33%
1 / 3 earnings
Positive
+7.4%
Q2 2025
Best reaction
-18.6%
Q1 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -18.6% | -26.0% | -16.8% | |
| Q3 2025 | -6.3% | -20.5% | -7.4% | |
| Q2 2025 | +7.4% | +20.8% | +13.2% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro